In the clinic, angiotensin receptor blockers (ARBs) as well as angiotensin-converting enzyme inhibitor (ACEI) have proven to lower the mortality rates of patients suffering from acute kidney disease (AKI) [97] as well as CKD [98]. This evidence concerns the gene ACE and acute kidney injury.